Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
Sponsor: Jonsson Comprehensive Cancer Center
Summary
The phase I/II trial assess the safety and efficacy of a new positron emission tomography (PET) test for early diagnosis of lung cancer. This study uses PET and Me-4FDG new glucose tracer (alpha-methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside) designed specifically to determine glucose update into cells in the body. PET is a non-invasive imaging method used to detect cancer in patient. Me4FDG is a radioactive glucose tracer used in PET to locate cells in the body taking up glucose by SGLT2. SLGT2 is a sodium glucose transport protein that accumulates glucose in some cells, e.g. kidney cells and tumors. This study may help researcher determine how effective PET with ME4FDG tracer works in detecting lung cancer.
Official title: Positron-Emission Tomography Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-01-19
Completion Date
2027-10-01
Last Updated
2025-11-10
Healthy Volunteers
No
Conditions
Interventions
Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
Given IV
Computed Tomography
Undergo PET/CT
Laboratory Biomarker Analysis
Correlative studies
Positron Emission Tomography
Undergo PET/CT
Locations (1)
Yesenia Calzada
Los Angeles, California, United States